Fresenius Medical Care (FMS) has released an update.
Fresenius Medical Care reported robust growth in its operating income margin for Q3 2024, driven by organic revenue growth and improved U.S. dialysis treatment volumes. The company exceeded its FME25 savings target, achieving significant cost reductions, and further optimized its portfolio by divesting non-core assets. With a positive outlook, Fresenius continues to focus on enhancing operational performance and financial stability.
For further insights into FMS stock, check out TipRanks’ Stock Analysis page.
